Cargando…

Pathogenic signal peptide variants in the human genome

Secreted and membrane proteins represent a third of all cellular proteins and contain N-terminal signal peptides that are required for protein targeting to endoplasmic reticulum (ER). Mutations in signal peptides affect protein targeting, translocation, processing, and stability, and are associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutierrez Guarnizo, Sneider Alexander, Kellogg, Morgana K, Miller, Sarah C, Tikhonova, Elena B, Karamysheva, Zemfira N, Karamyshev, Andrey L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583284/
https://www.ncbi.nlm.nih.gov/pubmed/37859801
http://dx.doi.org/10.1093/nargab/lqad093
_version_ 1785122517143257088
author Gutierrez Guarnizo, Sneider Alexander
Kellogg, Morgana K
Miller, Sarah C
Tikhonova, Elena B
Karamysheva, Zemfira N
Karamyshev, Andrey L
author_facet Gutierrez Guarnizo, Sneider Alexander
Kellogg, Morgana K
Miller, Sarah C
Tikhonova, Elena B
Karamysheva, Zemfira N
Karamyshev, Andrey L
author_sort Gutierrez Guarnizo, Sneider Alexander
collection PubMed
description Secreted and membrane proteins represent a third of all cellular proteins and contain N-terminal signal peptides that are required for protein targeting to endoplasmic reticulum (ER). Mutations in signal peptides affect protein targeting, translocation, processing, and stability, and are associated with human diseases. However, only a few of them have been identified or characterized. In this report, we identified pathogenic signal peptide variants across the human genome using bioinformatic analyses and predicted the molecular mechanisms of their pathology. We recovered more than 65 thousand signal peptide mutations, over 11 thousand we classified as pathogenic, and proposed framework for distinction of their molecular mechanisms. The pathogenic mutations affect over 3.3 thousand genes coding for secreted and membrane proteins. Most pathogenic mutations alter the signal peptide hydrophobic core, a critical recognition region for the signal recognition particle, potentially activating the Regulation of Aberrant Protein Production (RAPP) quality control and specific mRNA degradation. The remaining pathogenic variants (about 25%) alter either the N-terminal region or signal peptidase processing site that can result in translocation deficiencies at the ER membrane or inhibit protein processing. This work provides a conceptual framework for the identification of mutations across the genome and their connection with human disease.
format Online
Article
Text
id pubmed-10583284
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105832842023-10-19 Pathogenic signal peptide variants in the human genome Gutierrez Guarnizo, Sneider Alexander Kellogg, Morgana K Miller, Sarah C Tikhonova, Elena B Karamysheva, Zemfira N Karamyshev, Andrey L NAR Genom Bioinform Standard Article Secreted and membrane proteins represent a third of all cellular proteins and contain N-terminal signal peptides that are required for protein targeting to endoplasmic reticulum (ER). Mutations in signal peptides affect protein targeting, translocation, processing, and stability, and are associated with human diseases. However, only a few of them have been identified or characterized. In this report, we identified pathogenic signal peptide variants across the human genome using bioinformatic analyses and predicted the molecular mechanisms of their pathology. We recovered more than 65 thousand signal peptide mutations, over 11 thousand we classified as pathogenic, and proposed framework for distinction of their molecular mechanisms. The pathogenic mutations affect over 3.3 thousand genes coding for secreted and membrane proteins. Most pathogenic mutations alter the signal peptide hydrophobic core, a critical recognition region for the signal recognition particle, potentially activating the Regulation of Aberrant Protein Production (RAPP) quality control and specific mRNA degradation. The remaining pathogenic variants (about 25%) alter either the N-terminal region or signal peptidase processing site that can result in translocation deficiencies at the ER membrane or inhibit protein processing. This work provides a conceptual framework for the identification of mutations across the genome and their connection with human disease. Oxford University Press 2023-10-18 /pmc/articles/PMC10583284/ /pubmed/37859801 http://dx.doi.org/10.1093/nargab/lqad093 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of NAR Genomics and Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Standard Article
Gutierrez Guarnizo, Sneider Alexander
Kellogg, Morgana K
Miller, Sarah C
Tikhonova, Elena B
Karamysheva, Zemfira N
Karamyshev, Andrey L
Pathogenic signal peptide variants in the human genome
title Pathogenic signal peptide variants in the human genome
title_full Pathogenic signal peptide variants in the human genome
title_fullStr Pathogenic signal peptide variants in the human genome
title_full_unstemmed Pathogenic signal peptide variants in the human genome
title_short Pathogenic signal peptide variants in the human genome
title_sort pathogenic signal peptide variants in the human genome
topic Standard Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583284/
https://www.ncbi.nlm.nih.gov/pubmed/37859801
http://dx.doi.org/10.1093/nargab/lqad093
work_keys_str_mv AT gutierrezguarnizosneideralexander pathogenicsignalpeptidevariantsinthehumangenome
AT kelloggmorganak pathogenicsignalpeptidevariantsinthehumangenome
AT millersarahc pathogenicsignalpeptidevariantsinthehumangenome
AT tikhonovaelenab pathogenicsignalpeptidevariantsinthehumangenome
AT karamyshevazemfiran pathogenicsignalpeptidevariantsinthehumangenome
AT karamyshevandreyl pathogenicsignalpeptidevariantsinthehumangenome